

Clinical Applications of Multi-Omics Integration in Disease Diagnosis

Jerry Adesola Adeyemo

ABSTRACT

The rapid evolution of high-throughput biological technologies has transformed modern medicine, yet the clinical translation of these advances remains fragmented when single-omics approaches are used in isolation. Multi-omics integration, which combines genomic, transcriptomic, proteomic, metabolomic, and epigenomic data, offers a more comprehensive view of disease biology by capturing molecular interactions across multiple biological layers. In clinical settings, this integrative approach has demonstrated growing value in improving diagnostic accuracy, enabling earlier disease detection, and refining patient stratification, particularly for complex and heterogeneous conditions such as cancer, cardiovascular diseases, neurodegenerative disorders, and immune-mediated diseases. By linking molecular signatures to clinical phenotypes, multi-omics frameworks support the identification of robust biomarkers, uncover hidden disease subtypes, and enhance risk prediction beyond conventional diagnostic tools. Advances in bioinformatics, machine learning, and clinical data harmonization have further accelerated the feasibility of translating multi-omics insights into routine diagnostics. However, challenges remain, including data standardization, interpretability, cost, and ethical considerations related to data privacy and clinical decision-making. This review highlights current clinical applications of multi-omics integration in disease diagnosis, discusses representative case studies, and outlines key barriers and future directions for embedding multi-omics-driven diagnostics into precision medicine and real-world healthcare systems.

KEYWORDS: Multi-omics integration; disease diagnosis; precision medicine; clinical biomarkers; genomics; proteomics; metabolomics; systems biology.

ARTICLE DETAILS

Published On:
06 January 2026

Available on:
<https://ijmscrs.com>

1. INTRODUCTION

Clinical diagnosis has traditionally relied on observable symptoms, imaging, laboratory tests, and a limited set of molecular assays [1]. While these approaches have proven effective for many conditions, they often fail to capture the biological complexity underlying multifactorial and heterogeneous diseases. Advances in omics technologies have enabled comprehensive molecular profiling at unprecedented scale and resolution, allowing clinicians and researchers to interrogate biological systems in far greater detail. Genomics reveals inherited and somatic DNA variants, transcriptomics captures gene expression dynamics, proteomics reflects functional protein activity, and metabolomics provides insight into downstream metabolic states [2]. Epigenomics and microbiomics further add layers of regulatory and environmental influence.

Despite their individual strengths, single-omics approaches frequently provide an incomplete or fragmented view of disease biology. Diseases such as cancer, diabetes,

neurodegenerative disorders, and autoimmune conditions arise from complex interactions among genetic predisposition, regulatory mechanisms, environmental exposures, and lifestyle factors [3]. Multi-omics integration seeks to address this complexity by combining data across multiple molecular layers to generate a holistic representation of disease states [4, 5]. In the context of clinical diagnosis, this integrative paradigm has the potential to transform how diseases are detected, classified, and managed. This review focuses on the clinical applications of multi-omics integration in disease diagnosis. Rather than emphasizing purely methodological innovation, we center our discussion on translational relevance, clinical utility, and real-world diagnostic impact. We examine how multi-omics approaches are being used to identify diagnostic biomarkers, redefine disease categories, and support personalized diagnostic strategies across diverse clinical domains.

2. OVERVIEW OF OMICS TECHNOLOGIES RELEVANT TO CLINICAL DIAGNOSIS

2.1 Genomics

Genomics forms the foundation of many diagnostic applications, providing information on inherited variants, somatic mutations, copy number alterations, and structural rearrangements [6]. In clinical practice, genomic testing is widely used for diagnosing rare genetic disorders, hereditary cancers, and pharmacogenomic profiling [7]. Whole-genome sequencing and whole-exome sequencing have become increasingly accessible, enabling comprehensive variant discovery [8]. However, genomic alterations alone do not always predict disease onset or severity, highlighting the need for complementary omics layers.

2.2 Transcriptomics

Transcriptomics measures gene expression levels and captures dynamic changes in cellular states. RNA sequencing has been applied clinically to identify disease-specific expression signatures, detect gene fusions, and characterize immune responses [9]. In diagnostic settings, transcriptomic profiles can distinguish between disease subtypes that share similar genomic alterations but differ in biological behavior and clinical outcomes [10].

2.3 Proteomics

Proteomics provides a direct readout of functional molecules responsible for cellular processes. Protein abundance, post-translational modifications, and protein-protein interactions often correlate more closely with disease phenotypes than upstream genomic changes [11]. Advances in mass spectrometry and affinity-based assays have enabled increasingly sensitive and reproducible proteomic measurements, making proteomics an important component of diagnostic multi-omics strategies [12].

2.4 Metabolomics

Metabolomics captures small-molecule metabolites that reflect cellular metabolism and physiological states [13]. Because metabolites are influenced by genetic, environmental, and lifestyle factors, metabolomic profiles can serve as sensitive indicators of disease processes. In clinical diagnostics, metabolomics has shown value in identifying early disease markers, monitoring disease progression, and differentiating between similar clinical presentations [14].

2.5 Epigenomics and Microbiomics

Epigenomic modifications such as DNA methylation and histone modifications regulate gene expression without altering DNA sequence [15]. Epigenetic signatures are increasingly recognized as diagnostic markers, particularly in cancer and developmental disorders. Microbiomics, which characterizes microbial communities, has emerged as a critical factor in diseases ranging from gastrointestinal disorders to metabolic and neurological

conditions [16]. Integrating these layers with host omics data enhances diagnostic precision.

3. CLINICAL APPLICATIONS ACROSS DISEASE AREAS

Multi-omics integration has progressed from experimental proof-of-concept studies into a clinically relevant framework that is actively reshaping diagnostic practice across multiple disease domains. By simultaneously interrogating genomic variation, gene expression, protein activity, metabolic states, and regulatory mechanisms, clinicians are increasingly able to move beyond symptom-based and single-marker diagnostics. This integrative approach is particularly valuable in diseases characterized by biological heterogeneity, overlapping clinical presentations, and variable disease trajectories. In such contexts, multi-omics diagnostics provides a deeper molecular resolution that improves diagnostic accuracy, enables earlier detection, and supports clinically meaningful disease stratification.

3.1 Oncology

Cancer diagnosis represents one of the most mature and impactful applications of multi-omics integration in clinical medicine [17]. Tumors that appear histologically similar often exhibit profound molecular differences that influence aggressiveness, treatment response, and survival outcomes [18]. While traditional histopathology and immunohistochemistry remain foundational to cancer diagnosis, they frequently fail to capture the biological complexity that drives interpatient variability [19]. Multi-omics integration has enabled a transition toward molecularly informed cancer classification, allowing clinicians to diagnose cancer not only by tissue of origin but also by underlying biological behavior.

Breast cancer illustrates the clinical limitations of single-layer diagnostics and the value of integrative approaches. Standard diagnostic classification relies heavily on estrogen receptor, progesterone receptor, and HER2 status, yet a substantial proportion of patients with favorable receptor profiles experience treatment resistance or early recurrence. Multi-omics analyses combining somatic genomic mutations, transcriptomic expression signatures, and proteomic pathway activation have revealed additional biologically distinct subgroups within clinically defined categories [20]. In tertiary oncology centers, RNA sequencing is increasingly used alongside targeted DNA sequencing to identify transcriptional programs associated with immune evasion or therapy resistance, while proteomic analyses provide functional insight into signaling pathway activation that may not be apparent at the genomic level [21, 22].

Glioblastoma further explains the diagnostic power of multi-omics integration. Although genomic markers such as IDH mutation status and MGMT promoter methylation are clinically informative, they do not fully account for the wide variability in patient outcomes [23]. Integrative studies

Clinical Applications of Multi-Omics Integration in Disease Diagnosis

incorporating genomics, epigenomics, transcriptomics, and metabolomics have identified molecularly distinct glioblastoma subtypes associated with differential metabolic dependencies and survival trajectories [24, 25]. DNA methylation profiling has already entered clinical diagnostic workflows in some neuropathology laboratories, demonstrating how multi-omics-derived tools can improve tumor classification and prognostic accuracy.

Liquid biopsy technologies represent another major diagnostic advance in oncology. In lung cancer, integration

of circulating tumor DNA sequencing with plasma proteomics and metabolomics has improved the differentiation of malignant versus benign pulmonary nodules, particularly in early-stage disease [26]. These approaches are especially valuable for patients who are not candidates for invasive biopsy procedures, reducing diagnostic risk while maintaining high sensitivity and specificity as described in Table 1 below.

Table 1: Multi-Omics Integration in Oncology Diagnosis

Cancer Type	Integrated Omics Layers	Diagnostic Contribution
Breast cancer	Genomics, transcriptomics, proteomics	Identification of molecular subtypes beyond receptor status
Glioblastoma	Genomics, epigenomics, transcriptomics, metabolomics	Improved tumor classification and prognostic stratification
Lung cancer	ctDNA genomics, proteomics, metabolomics	Early detection and non-invasive diagnosis
Colorectal cancer	Genomics, transcriptomics, microbiomics	Molecular subtype differentiation and risk stratification

3.2 Cardiovascular Diseases

Cardiovascular diseases remain a leading cause of global mortality, yet diagnostic approaches often identify disease only after irreversible damage has occurred. Traditional risk assessment models rely on demographic and clinical factors such as age, blood pressure, cholesterol levels, and smoking history, which inadequately capture underlying biological heterogeneity [27]. Multi-omics integration has enabled earlier and more individualized diagnostic evaluation by uncovering molecular signatures associated with disease initiation and progression.

In coronary artery disease, polygenic risk scores derived from large genomic datasets identify individuals with inherited susceptibility, but these scores alone do not reflect environmental exposures, inflammatory processes, or metabolic dysregulation [28]. When genomic risk information is integrated with transcriptomic profiles from peripheral blood and metabolomic markers related to lipid metabolism and systemic inflammation, clinicians can achieve a more refined diagnostic assessment. Studies have shown that patients with similar clinical risk profiles but distinct multi-omics signatures may experience markedly different disease trajectories, highlighting the diagnostic limitations of conventional tools.

Heart failure diagnosis also benefits from integrative approaches. Differentiating heart failure with preserved ejection fraction from reduced ejection fraction remains clinically challenging due to overlapping symptoms and nonspecific imaging findings. Multi-omics analyses combining proteomic biomarkers of myocardial stress and fibrosis with transcriptomic indicators of immune activation and metabolic dysfunction have improved diagnostic

discrimination between these subtypes [29, 30]. Such stratification is clinically important, as treatment strategies and prognoses differ substantially between heart failure phenotypes.

3.3 Neurological and Neurodegenerative Disorders

Neurological and neurodegenerative disorders present unique diagnostic challenges due to limited access to affected tissue, long preclinical phases, and overlapping clinical symptoms. Multi-omics integration has opened new diagnostic pathways by enabling the detection of molecular changes that precede overt clinical manifestations [31]. In Alzheimer’s disease, genetic risk factors such as APOE variants provide population-level risk information but lack sufficient predictive accuracy for individual diagnosis [32]. Integrating genomic data with cerebrospinal fluid proteomics and plasma metabolomics has enabled the identification of molecular signatures associated with early neurodegeneration, synaptic dysfunction, and neuroinflammation [33]. Some specialized memory clinics now incorporate multi-analyte biomarker panels informed by multi-omics research to support differential diagnosis between Alzheimer’s disease and other dementias. Parkinson’s disease provides another clinically relevant example. Transcriptomic and proteomic profiling of blood and cerebrospinal fluid, combined with metabolomic indicators of mitochondrial dysfunction and oxidative stress, has enabled the identification of diagnostic signatures that distinguish Parkinson’s disease from atypical parkinsonian syndromes [34, 35]. Early diagnostic accuracy is critical for patient counseling, prognosis, and enrollment in disease-modifying clinical trials.

3.4 Metabolic and Endocrine Disorders

Metabolic and endocrine diseases are biologically heterogeneous but are often diagnosed using a narrow set of clinical markers. Multi-omics integration has revealed previously unrecognized disease subtypes with important diagnostic and prognostic implications. In type 2 diabetes, genomic variants linked to insulin secretion and insulin resistance provide partial insight into disease risk. When integrated with transcriptomic data from adipose tissue and metabolomic profiles reflecting lipid and amino acid metabolism, clinicians can distinguish patients whose disease is primarily driven by beta-cell dysfunction from those with predominant insulin resistance [36, 37]. This distinction is diagnostically important, particularly in early disease stages where conventional markers may be inconclusive. Rare metabolic disorders further illustrate the clinical value of integration [38]. Inborn errors of metabolism often present with nonspecific symptoms, leading to delayed diagnosis. Combining genomic sequencing with targeted metabolomic profiling has significantly improved diagnostic yield, reduced diagnostic odysseys, and enabled earlier intervention, particularly in pediatric populations.

3.5 Infectious and Immune-Mediated Diseases

Accurate diagnosis of infectious and immune-mediated diseases requires distinguishing pathogen-driven processes from host immune responses. Multi-omics integration has enhanced diagnostic precision in both acute and chronic immune conditions. During viral infections, host transcriptomic signatures can reliably differentiate viral from bacterial etiologies, even when clinical symptoms overlap [39]. When combined with proteomic markers of immune activation and metabolomic indicators of systemic inflammation, clinicians can make more informed diagnostic decisions, particularly in emergency and critical care settings where rapid triage is essential [40]. Autoimmune diseases such as systemic lupus erythematosus further highlight the diagnostic value of integration. Genomic susceptibility loci, transcriptomic immune signatures, and proteomic autoantibody profiles together provide a more comprehensive diagnostic framework than any single modality [41]. Integrative biomarker panels are increasingly used in rheumatology clinics to support diagnosis in patients with early or atypical disease presentations.

4. CHALLENGES AND LIMITATIONS

Despite its transformative potential, the clinical adoption of multi-omics diagnostics remains constrained by several interconnected challenges that span technical, clinical, economic, and ethical domains. Addressing these limitations is essential for translating multi-omics integration from specialized research environments into routine, equitable healthcare practice. One of the most significant barriers is **cost**. Comprehensive multi-omics profiling requires advanced sequencing platforms, high-resolution mass spectrometry, specialized reagents, and robust

computational infrastructure. While the cost of individual omics technologies has decreased over time, integrating multiple layers substantially increases overall diagnostic expense. These costs extend beyond data generation to include bioinformatics expertise, long-term data storage, and continuous system maintenance. As a result, multi-omics diagnostics are currently concentrated in well-funded academic medical centers and are largely inaccessible in low-resource settings, raising concerns about widening global and domestic health inequities.

Data complexity and scale present another major limitation. Multi-omics datasets are inherently high-dimensional, heterogeneous, and noisy, with each omics layer differing in measurement scale, temporal dynamics, and biological interpretation. Integrating these datasets in a way that preserves biological meaning while avoiding spurious associations remains a significant analytical challenge. In clinical contexts, where decisions must be timely and reliable, overly complex models can hinder adoption if results are difficult to reproduce or validate across independent cohorts. Moreover, the lack of universally accepted standards for data preprocessing, normalization, and integration complicates cross-study comparisons and clinical benchmarking.

Closely related is the issue of clinical interpretability. While advanced machine learning and artificial intelligence methods have improved the ability to identify diagnostic signatures from multi-omics data, many of these models function as “black boxes.” Clinicians often require clear mechanistic explanations to trust and act upon diagnostic outputs, particularly when results may influence high-stakes decisions such as cancer diagnosis or early intervention in neurodegenerative disease. The gap between statistically robust predictions and clinically interpretable insights remains a critical hurdle for routine use.

Interoperability and integration with clinical systems further limit implementation. Most healthcare systems rely on electronic health records that were not designed to accommodate large-scale molecular data. Integrating multi-omics results into existing clinical workflows, decision-support tools, and regulatory reporting frameworks is technically challenging and often institution-specific. Without seamless interoperability, multi-omics diagnostics risk remaining siloed within research units rather than informing everyday clinical care.

Ethical and legal considerations also play a central role. Multi-omics data are deeply personal, often revealing information not only about an individual patient but also about biological relatives. Ensuring **data privacy, informed consent, and secure data sharing** is increasingly complex as datasets grow in size and are reused across studies and institutions. Patients may not fully understand the long-term implications of omics data generation, including incidental findings or future reanalysis. Regulatory frameworks have struggled to keep pace with these realities, creating uncertainty for clinicians and researchers alike. In summary,

Clinical Applications of Multi-Omics Integration in Disease Diagnosis

while multi-omics integration offers unprecedented opportunities for improving disease diagnosis, its clinical translation is constrained by cost, data complexity, interpretability, system-level integration challenges, and ethical concerns. Overcoming these barriers will require coordinated efforts among clinicians, data scientists, healthcare institutions, policymakers, and patient communities to ensure that multi-omics diagnostics are not only scientifically robust but also clinically practical, ethically sound, and broadly accessible.

5. FUTURE DIRECTIONS AND CLINICAL TRANSLATION

The future of multi-omics integration in disease diagnosis lies in its successful transition from highly specialized research settings into scalable, clinically actionable tools that can be routinely deployed across healthcare systems. Achieving this translation will require coordinated progress in technology development, clinical validation, workforce training, regulatory frameworks, and health system integration.

A critical future direction is the development of standardized and clinically optimized multi-omics workflows. Current multi-omics studies often rely on customized protocols that vary across institutions, limiting reproducibility and clinical trust. Moving forward, harmonized standards for sample collection, processing, data normalization, and integration will be essential. Clinical-grade assays that prioritize robustness, speed, and cost-effectiveness over maximal molecular depth are likely to gain traction. In this context, targeted multi-omics panels, rather than comprehensive whole-omics profiling, may represent a pragmatic path toward clinical adoption, particularly for specific diagnostic indications.

Clinical validation and real-world evidence generation will play a central role in translation. Future efforts must move beyond retrospective cohort studies to include prospective, multi-center clinical trials that demonstrate how multi-omics diagnostics improve patient outcomes, reduce diagnostic uncertainty, or optimize resource utilization. Embedding multi-omics tools within existing clinical care pathways, such as oncology tumor boards or cardiovascular risk clinics, will allow clinicians to assess their added value compared to standard diagnostic approaches. Importantly, regulatory approval and payer reimbursement will depend on clear evidence of clinical utility, not just analytical performance.

Advances in computational methods and interpretability-focused artificial intelligence will further shape clinical translation. While sophisticated machine learning models have already shown strong predictive performance, future tools must emphasize transparency and clinician-facing interpretability. Hybrid models that integrate biological knowledge, such as pathway-based or network-informed frameworks, are likely to gain prominence because

they align more closely with clinical reasoning. Decision-support systems that translate complex multi-omics outputs into concise, actionable diagnostic insights will be critical for adoption in busy clinical environments.

Integration with electronic health records and clinical decision support **systems** represents another essential frontier. For multi-omics diagnostics to be clinically useful, results must be delivered in formats that are easily accessible and interpretable within routine workflows. Future healthcare systems will need infrastructure capable of securely storing omics data, linking molecular profiles to longitudinal clinical records, and supporting real-time decision-making. Interoperable platforms that allow clinicians to visualize molecular signatures alongside imaging, laboratory values, and clinical notes will enhance diagnostic coherence and usability.

Workforce development and interdisciplinary collaboration will also shape the future landscape. Clinicians, laboratory scientists, and bioinformaticians must work together to ensure appropriate interpretation and use of multi-omics diagnostics. Training programs that equip healthcare professionals with foundational literacy in omics technologies and data interpretation will be essential. Similarly, the emergence of clinical molecular tumor boards and multidisciplinary diagnostic teams highlights the need for collaborative models that bridge the gap between data generation and clinical action.

From a broader perspective, equity and global implementation must be central to future translation efforts. Expanding multi-omics diagnostics beyond high-resource academic centers will require cost-reduction strategies, scalable platforms, and inclusion of diverse populations in discovery and validation studies. Portable technologies, cloud-based analytics, and regional data-sharing networks may enable broader access, particularly in underserved and low-resource settings. Ensuring that diagnostic models are trained and validated across diverse genetic, environmental, and socioeconomic contexts will improve both fairness and accuracy. In conclusion, the clinical translation of multi-omics integration will depend on a balanced approach that combines technological innovation with rigorous validation, interpretability, system-level integration, and ethical responsibility. As these elements converge, multi-omics diagnostics have the potential to redefine disease diagnosis, shifting healthcare toward earlier detection, greater precision, and more personalized clinical decision-making.

6. CONCLUSION

Multi-omics integration marks a fundamental shift in how diseases are understood and diagnosed in clinical medicine. Rather than relying on single biomarkers or isolated molecular signals, this approach captures the dynamic interplay between genetic variation, gene regulation, protein function, metabolic activity, and environmental influences. By assembling these layers into a coherent

biological framework, multi-omics diagnostics provides a deeper and more clinically meaningful representation of disease states, particularly for complex, heterogeneous, and multifactorial conditions that have historically challenged conventional diagnostic models. Across diverse disease areas, the evidence reviewed in this manuscript demonstrates that multi-omics integration improves diagnostic precision by uncovering molecular subtypes that are invisible to traditional clinical and single-omics approaches. In oncology, it refines tumor classification and supports earlier, less invasive detection strategies. In cardiovascular, neurological, metabolic, and immune-mediated diseases, it enables earlier risk identification, clearer differentiation between overlapping disease phenotypes, and more accurate prognostic assessment. These advances directly address longstanding diagnostic gaps that contribute to delayed treatment, misclassification, and suboptimal patient outcomes.

While significant challenges remain, including cost, data complexity, and system-level integration, the trajectory of technological innovation and analytical refinement suggests that these barriers are surmountable. Targeted multi-omics panels, interpretable analytical models, and standardized clinical workflows are already narrowing the gap between research and routine care. As validation efforts expand and real-world evidence accumulates, multi-omics diagnostics is likely to transition from a specialized capability to a core component of modern diagnostic practice. In the coming years, the success of multi-omics integration in disease diagnosis will depend not only on scientific progress but also on thoughtful implementation. Ensuring equitable access, ethical data governance, clinician engagement, and patient trust will be as critical as technological advancement. When these elements align, multi-omics diagnostics has the potential to redefine diagnostic standards, enabling earlier detection, more accurate disease classification, and ultimately better health outcomes across diverse patient populations. In conclusion, multi-omics integration is not merely an incremental improvement to existing diagnostic methods but a paradigm shift in clinical reasoning and disease characterization. As it becomes embedded within healthcare systems, it promises to transform diagnosis from a reactive process into a proactive, biology-driven foundation for precision medicine and future-ready healthcare.

REFERENCES

- I. Chen C, Wang J, Pan D, Wang X, Xu Y, Yan J, Wang L, Yang X, Yang M, Liu GP. Applications of multi-omics analysis in human diseases. *MedComm*. 2023 Aug;4(4):e315.
- II. Wekesa JS, Kimwele M. A review of multi-omics data integration through deep learning approaches for disease diagnosis, prognosis, and treatment. *Frontiers in Genetics*. 2023 Jul 20;14:1199087.
- III. Shahrajabian MH, Sun W. Survey on multi-omics, and multi-omics data analysis, integration and application. *Current Pharmaceutical Analysis*. 2023 May 1;19(4):267-81.
- IV. Subramanian I, Verma S, Kumar S, Jere A, Anamika K. Multi-omics data integration, interpretation, and its application. *Bioinformatics and biology insights*. 2020 Jan;14:1177932219899051.
- V. Sibilio P, De Smaele E, Paci P, Conte F. Integrating multi-omics data: Methods and applications in human complex diseases. *Biotechnology Reports*. 2025 Nov 15:e00938.
- VI. D'Adamo GL, Widdop JT, Giles EM. The future is now? Clinical and translational aspects of "Omics" technologies. *Immunology and cell biology*. 2021 Feb;99(2):168-76.
- VII. Boyd SD, Galli SJ, Schrijver I, Zehnder JL, Ashley EA, Merker JD. A balanced look at the implications of genomic (and other "omics") testing for disease diagnosis and clinical care. *Genes*. 2014 Sep 1;5(3):748-66.
- VIII. Horgan RP, Kenny LC. 'Omic' technologies: genomics, transcriptomics, proteomics and metabolomics. *Obstetrician & Gynaecologist*. 2011 Jul 1;13(3).
- IX. Sager M, Yeat NC, Pajaro-Van der Stadt S, Lin C, Ren Q, Lin J. Transcriptomics in cancer diagnostics: developments in technology, clinical research and commercialization. *Expert Review of Molecular Diagnostics*. 2015 Dec 2;15(12):1589-603.
- X. Tagoe B, Quainoo L, Amponsah SK. Current technological approaches to the utility of omics (metabolomics, lipidomics, genomics, and transcriptomics) in renal diseases diagnosis, prognosis, and treatment. In *Understanding Renal Biochemistry* 2026 Jan 1 (pp. 145-166). Academic Press.
- XI. Latterich M, Abramovitz M, Leyland-Jones B. Proteomics: new technologies and clinical applications. *European Journal of Cancer*. 2008 Dec 1;44(18):2737-41.
- XII. López E, Madero L, López-Pascual J, Latterich M. Clinical proteomics and OMICS clues useful in translational medicine research. *Proteome science*. 2012 May 29;10(1):35.
- XIII. Cheung PK, Ma MH, Tse HF, Yeung KF, Tsang HF, Chu MK, Kan CM, Cho WC, Ng LB, Chan LW, Wong SC. The applications of metabolomics in the molecular diagnostics of cancer. *Expert review of molecular diagnostics*. 2019 Sep 2;19(9):785-93.
- XIV. Odom JD, Sutton VR. Metabolomics in clinical practice: improving diagnosis and informing management. *Clinical chemistry*. 2021 Dec 1;67(12):1606-17.

Clinical Applications of Multi-Omics Integration in Disease Diagnosis

- XV. Shuja N. The impact of omics technologies on advancing developmental medicine. DEVELOPMENTAL MEDICO-LIFE-SCIENCES Учредители: Developmental Medico-Life-Sciences Research and Publications (SMC-Private) Limited. 2024;1(5):1-4.
- XVI. Srivastava U, Kanchan S, Kesheri M, Gupta MK, Singh S. Types of omics data: genomics, metagenomics, epigenomics, transcriptomics, proteomics, metabolomics, and phenomics. In: Integrative Omics 2024 Jan 1 (pp. 13-34). Academic Press.
- XVII. Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. Journal of nuclear medicine. 2001 Mar 1;42(3):432-45.
- XVIII. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004 May;231(2):305-32.
- XIX. Akhoundova D, Rubin MA. Clinical application of advanced multi-omics tumor profiling: Shaping precision oncology of the future. Cancer Cell. 2022 Sep 12;40(9):920-38.
- XX. Quezada H, Guzmán-Ortiz AL, Díaz-Sánchez H, Valle-Rios R, Aguirre-Hernández J. Omics-based biomarkers: current status and potential use in the clinic. Boletín Médico Del Hospital Infantil de México (English Edition). 2017 May 1;74(3):219-26.
- XXI. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clinical cancer research. 2009 Jan 15;15(2):431-40.
- XXII. Yoo BC, Kim KH, Woo SM, Myung JK. Clinical multi-omics strategies for the effective cancer management. Journal of proteomics. 2018 Sep 30;188:97-106.
- XXIII. Menyhárt O, Györfy B. Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis. Computational and structural biotechnology journal. 2021 Jan 1;19:949-60.
- XXIV. Hernandez-Martinez JM, Sánchez-Reyes R, De la Garza-Salazar JG, Arrieta O. Onco-omics approaches and applications in clinical trials for cancer patients. Translational research and Onco-Omics applications in the era of cancer personal genomics. 2019 Nov 12;79-90.
- XXV. Schmidt DR, Patel R, Kirsch DG, Lewis CA, Vander Heiden MG, Locasale JW. Metabolomics in cancer research and emerging applications in clinical oncology. CA: a cancer journal for clinicians. 2021 Jul;71(4):333-58.
- XXVI. Rhee JW, Ky B, Armenian SH, Yancy CW, Wu JC. Primer on biomarker discovery in cardio-oncology: application of omics technologies. Cardio Oncology. 2020 Sep 1;2(3):379-84.
- XXVII. Leon-Mimila P, Wang J, Huertas-Vazquez A. Relevance of multi-omics studies in cardiovascular diseases. Frontiers in cardiovascular medicine. 2019 Jul 17;6:91.
- XXVIII. Sohag MM, Raqib SM, Akhmad SA. OMICS approaches in cardiovascular diseases: a mini review. Genomics & Informatics. 2021 Jun 30;19(2):e13.
- XXIX. Banerjee S, Prabhu Basrur N, Rai PS. Omics technologies in personalized combination therapy for cardiovascular diseases: Challenges and opportunities. Personalized Medicine. 2021 Nov 1;18(6):595-611.
- XXX. Doran S, Arif M, Lam S, Bayraktar A, Turkez H, Uhlen M, Boren J, Mardinoglu A. Multi-omics approaches for revealing the complexity of cardiovascular disease. Briefings in bioinformatics. 2021 Sep;22(5):bbab061.
- XXXI. La Cognata V, Morello G, Cavallaro S. Omics data and their integrative analysis to support stratified medicine in neurodegenerative diseases. International Journal of Molecular Sciences. 2021 May 1;22(9):4820.
- XXXII. Chen C, Wang J, Pan D, Wang X, Xu Y, Yan J, Wang L, Yang X, Yang M, Liu GP. Applications of multi-omics analysis in human diseases. MedComm. 2023 Aug;4(4):e315.
- XXXIII. Zhao N, Quicksall Z, Asmann YW, Ren Y. Network approaches for omics studies of neurodegenerative diseases. Frontiers in Genetics. 2022 Sep 16;13:984338.
- XXXIV. Krokidis MG, Exarchos TP, Vlamos P. Data-driven biomarker analysis using computational omics approaches to assess neurodegenerative disease progression. Math Biosci Eng. 2021 Feb 22;18(2):1813-32.
- XXXV. Legati A, Giacomuzzi E, Spinazzi M, Lek M. Application of Omics Approaches to the Diagnosis of Genetic Neurological Disorders. Frontiers in Neurology. 2021 Jul 7;12:712010.
- XXXVI. Peliciari-Garcia RA, de Barros CF, Secio-Silva A, de Barros Peruchetti D, Romano RM, Bargi-Souza P. Multi-omics Investigations in Endocrine Systems and Their Clinical Implications. In: Mass Spectrometry-Based Approaches for Treating Human Diseases and Diagnostics 2024 Feb 27 (pp. 187-209). Cham: Springer International Publishing.
- XXXVII. Costanzo M, Aleidi SM, Abdel Rahman A. Omics in endocrinology: from biomarker discovery to targeting therapeutic strategies. Frontiers in Molecular Biosciences. 2025 Feb 13;12:1567250.
- XXXVIII. Vanamala JK, Sivaramakrishnan V, Mummidi S. Integrated multi-omic studies of metabolic

Clinical Applications of Multi-Omics Integration in Disease Diagnosis

syndrome, diabetes and insulin-related disorders: mechanisms, biomarkers, and therapeutic targets. *Frontiers in Endocrinology*. 2025 Jan 10;15:1537554.

- XXXIX. Ota M, Fujio K. Multi-omics approach to precision medicine for immune-mediated diseases. *Inflammation and regeneration*. 2021 Aug 1;41(1):23.
- XL. Borrego-Yaniz G, Terrón-Camero LC, Kerick M, Andrés-León E, Martín J. A holistic approach to understanding immune-mediated inflammatory diseases: bioinformatic tools to integrate omics data. *Computational and Structural Biotechnology Journal*. 2024 Dec 1;23:96-105.
- XLI. Anchang CG, Xu C, Raimondo MG, Atreya R, Maier A, Schett G, Zaburdaev V, Rauber S, Ramming A. The potential of OMICs technologies for the treatment of immune-mediated inflammatory diseases. *International Journal of Molecular Sciences*. 2021 Jul 13;22(14):7506.